FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC

Muscle invasive bladder cancer (MIBC) is a life-threatening malignancy with a five-year overall survival of approximately 50 to 60%. Bladder cancer was the 14th leading cause of cancer death in the world in 2018, with approximately 200,000 deaths related to bladder cancer that year. Traditionally, the cornerstone of curative treatment of MIBC is a radical cystectomy (RC), which involves the removal of the bladder, a pelvic lymph node dissection and reconstruction of the urinary tract. However, RC is associated with a significant perioperative mortality risk with high readmission rates, substantial morbidity and changes in patient's quality of life (QOL).